Diana Lourenco Carlson

Mrs. Diana Lourenco Carlson

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2024 in mBio
Verified
Journal Article
Open access
CSCharles Specht
Charles Specht
RWRUIYING WANG
RUIYING WANG
LOLorena V N Oliveira
Lorena V N Oliveira
MHMaureen M. Hester
Maureen M. Hester
CGChristina Gomez
Christina Gomez
SLStuart Levitz
Stuart Levitz
The global burden of infections due to the pathogenic fungus Cryptococcus is substantial in persons with low CD4 + T-cell counts. Previously, we deleted three chitin deacetylase genes from Cryptococcus neoformans to create a chitosan-deficient, avirulent strain, designated as cda1∆2∆3∆ , which, when used as a vaccine, protected mice from challenge with virulent C. neoformans strain KN99. Here, we explored the immunological basis for protection. Vaccine-mediated protection was maintained in mice lacking B cells or CD8 + T cells. In contrast, protection was lost in mice lacking α/β T cells or CD4 + T cells. Moreover, CD4 + T cells from vaccinated mice conferred protection upon adoptive transfer to naive mice. Importantly, while monoclonal antibody-mediated depletion of CD4 + T cells just prior to vaccination resulted in complete loss of protection, significant protection was retained in mice depleted of CD4 + T cells after vaccination but prior to challenge. Vaccine-mediated protection was lost in mice genetically deficient in interferon-γ (IFNγ), tumor necrosis factor alpha (TNFα), or interleukin (IL)-23p19. A robust influx of leukocytes and IFNγ- and TNFα-expressing CD4 + T cells was seen in the lungs of vaccinated and challenged mice. Finally, a higher level of IFNγ production by lung cells stimulated ex vivo correlated with lower fungal burden in the lungs. Thus, while B cells and CD8 + T cells are dispensable, IFNγ and CD4 + T cells have overlapping roles in generating protective immunity prior to cda1∆2∆3∆ vaccination. However, once vaccinated, protection becomes less dependent on CD4 + T cells, suggesting a strategy for vaccinating HIV + persons prior to loss of CD4 + T cells. IMPORTANCE: The fungus Cryptococcus neoformans is responsible for >100,000 deaths annually, mostly in persons with impaired CD4 + T-cell function such as AIDS. There are no approved human vaccines. We previously created a genetically engineered avirulent strain of C. neoformans , designated as cda1∆2∆3∆ . When used as a vaccine, cda1∆2∆3∆ protects mice against a subsequent challenge with a virulent C. neoformans strain. Here, we defined components of the immune system responsible for vaccine-mediated protection. We found that while B cells and CD8 + T cells were dispensible, protection was lost in mice genetically deficient in CD4 + T cells and the cytokines IFNγ, TNFα, or IL-23. A robust influx of cytokine-producing CD4 + T cells was seen in the lungs of vaccinated mice following infection. Importantly, protection was retained in mice depleted of CD4 + T cells following vaccination, suggesting a strategy to protect persons who are at risk of future CD4 + T-cell dysfunction.

16 December 2025 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
DCDiana Lourenco Carlson
Diana Lourenco Carlson
RWRUIYING WANG
RUIYING WANG
ZHZachary Hastings
Zachary Hastings
LOLorena V N Oliveira
Lorena V N Oliveira
MHMaureen M. Hester
Maureen M. Hester
SLStuart Levitz
Stuart Levitz
Infections with strains of the Cryptococcus neoformans species complex are responsible for over 100,000 deaths per year, predominantly due to meningitis in immunocompromised individuals. Despite much research, there are no licensed fungal vaccines available. Most experimental cryptococcal vaccine formulations have been tested in preclinical models using laboratory strains of C. neoformans, particularly H99 and KN99. However, to be effective, vaccines need to protect against the wide variety of cryptococcal isolates found worldwide, particularly in regions that have the highest burden of infections. Therefore, we explored vaccine-mediated protection of BALB/c mice against experimental cryptococcosis due to six C. neoformans strains originally isolated from patients with cryptococcal meningitis in Vietnam, Uganda, and Botswana. Two vaccines were tested: a live-attenuated C. neoformans vaccine lacking three chitin deacetylase genes, and a quadrivalent subunit protein vaccine adjuvanted with Cationic Adjuvant Formulation 01. When compared to unvaccinated mice, both vaccines provided significant protection against all six clinical strains. However, the degree of protection varied as a function of vaccine formulation and clinical strain. Lung leukocytes from vaccinated and infected mice had significantly increased antigen-stimulated interferon-gamma production compared with infected but unvaccinated mice. Thus, although the degree of protection varied, two cryptococcal vaccines significantly protected mice against experimental infection with cryptococcal strains representative of regions of the world that account for the majority of cryptococcal meningitis cases found globally. These data provide preclinical support for trialing vaccines in persons at high risk for developing cryptococcosis.

14 October 2026 in mBio
Verified
Journal Article
Open access
CSCharles Specht
Charles Specht
LOLorena V N Oliveira
Lorena V N Oliveira
DCDiana Lourenco Carlson
Diana Lourenco Carlson
MHMaureen M. Hester
Maureen M. Hester
SSSatya Sahu
Satya Sahu
SLStuart Levitz
Stuart Levitz
Infections due to Cryptococcus species are estimated to cause over 100,000 deaths a year. No cryptococcal vaccines are approved for human use. We have shown that vaccine formulations consisting of C. neoformans chitin deacetylase 2 (Cda2) and Cda1 adjuvanted with Cationic Adjuvant Formulation 01 (CAF01) protect mice against experimental cryptococcosis by a mechanism dependent upon CD4 + T cells. Here, using overlapping peptide libraries, we mapped epitopes in Cda2 and Cda1 that stimulated interferon-gamma (IFNγ) release from splenocytes of C57BL/6 and DR4 mice immunized with these proteins. DR4 mice lack mouse major histocompatibility class II (MHC-II) proteins and express chimeric MHC-II proteins with the specificity of the human HLA-DR allele, HLA-DRB1*04:01. Experimental results were then compared with MHC-II binding predictions using the Immune Epitope Database NetMHCIIpan 4.1 BA MHC-II epitope prediction tool. Unique epitopes in Cda2 and Cda1 were discovered for each mouse strain, some of which were not predicted to bind well to MHC-II. CD4 + T cells were responsible for cytokine release as IFNγ production was lost if CD4 + T cells were depleted from the splenocyte population. Finally, we tested a hybrid recombinant protein that consisted of portions of Cda2 and Cda1 containing the MHC-II/CD4 + T-cell epitopes that induce CD4 + T cells in DR4 mice. When administered as a CAF01-adjuvanted vaccine, the hybrid protein protected DR4 mice from an otherwise lethal C. neoformans pulmonary challenge. These results provide a proof of principle regarding the utility of MHC-II/CD4 + T-cell epitope mapping in cryptococcal vaccine development. IMPORTANCE: The development of vaccines to prevent cryptococcosis, a fungal disease which causes over 100,000 deaths annually, is a public health priority. We have demonstrated that adjuvanted vaccines containing two Cryptococcus neoformans protein antigens, chitin deacetylase (Cda)2 and Cda1, protect mice against experimental cryptococcosis by a mechanism dependent upon CD4 + T cells. In this study, we determined which 15-amino-acid peptides of Cda2 and Cda1 stimulate CD4 + T cells in C57BL/6 and DR4 mice; the latter mouse strain has human major histocompatibility class II (MHC-II) specificity. We then synthesized a small hybrid protein containing those portions of Cda2 and Cda1 that strongly stimulated CD4 + T-cell responses in DR4 mice. As an adjuvanted vaccine, the hybrid Cda2/1 protein protected DR4 mice from a C. neoformans pulmonary challenge. Thus, CD4 + T-cell/MHC-II epitope mapping experimentally validated the design of a protective multi-epitope protein for use in cryptococcal vaccines.

30 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
DCDiana Lourenco Carlson
Diana Lourenco Carlson
RWRUIYING WANG
RUIYING WANG
ZHZachary Hastings
Zachary Hastings
LOLorena V N Oliveira
Lorena V N Oliveira
MHMaureen M. Hester
Maureen M. Hester
SLStuart Levitz
Stuart Levitz
Infections with strains of the Cryptococcus neoformans species complex are responsible for over 100,000 deaths per year, predominantly due to meningitis in immunocompromised individuals. Despite much research, there are no licensed fungal vaccines available. Most experimental cryptococcal vaccine formulations have been tested in preclinical models using laboratory strains of C. neoformans, particularly H99 and KN99. However, to be effective, vaccines need to protect against the wide variety of cryptococcal isolates found worldwide, particularly in regions that have the highest burden of infections. Therefore, we explored vaccine-mediated protection of BALB/c mice against experimental cryptococcosis due to six C. neoformans strains originally isolated from patients with cryptococcal meningitis in Vietnam, Uganda, and Botswana. Two vaccines were tested: a live-attenuated C. neoformans vaccine lacking three chitin deacetylase genes and a quadrivalent subunit protein vaccine adjuvanted with Cationic Adjuvant Formulation 01. When compared to unvaccinated mice, both vaccines provided significant protection against all six clinical strains. However, the degree of protection varied as a function of vaccine formulation and clinical strain. Lung leukocytes from vaccinated and infected mice had significantly increased antigen-stimulated interferon-gamma production compared with infected but unvaccinated mice. Thus, although the degree of protection varied, two cryptococcal vaccines significantly protected mice against experimental infection with cryptococcal strains representative of regions of the world that account for the majority of cryptococcal meningitis cases found globally. These data provide preclinical support for trialing vaccines in persons at high risk for developing cryptococcosis.

2 June 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
HHHannah M Hamad
Hannah M Hamad
CSCharles Specht
Charles Specht
DCDiana Lourenco Carlson
Diana Lourenco Carlson
VYVikas Yadav
Vikas Yadav
RURajendra Upadhya
Rajendra Upadhya
SLStuart Levitz
Stuart Levitz
Cutaneous cryptococcosis, although rare, may arise as primary inoculation or as part of disseminated cryptococcal infection, particularly in immunocompromised hosts. We present the case of an 80-year-old man with type 2 diabetes mellitus receiving corticosteroid therapy for cryptogenic organizing pneumonia who developed cryptococcal cellulitis with a markedly elevated serum cryptococcal antigen (CrAg) titer but no discernible central nervous system (CNS) involvement. As high serum CrAg titers are strongly associated with CNS disease, we compared the patient isolate (designated MA-1) with the Cryptococcus neoformans reference strain KN99, using in vitro growth curves, a murine pulmonary infection model, and whole-genome sequencing. MA-1 grew more slowly than KN99 in tissue culture medium. Mice infected with MA-1 survived longer than those challenged with KN99, although brain dissemination of MA-1 still occurred by day 14, indicating that the strain was neurotropic. Genomic analysis revealed overall similarity to the C neoformans H99 strain but with distinctive structural features, including duplication of chromosome 12, a large deletion on chromosome 5, and multiple single-nucleotide polymorphisms. These alterations may have contributed to altered dissemination dynamics. This case underscores the importance of considering cryptococcosis in refractory cellulitis in immunocompromised patients. High CrAg titers, even without CNS findings, should prompt lumbar puncture and consideration of induction therapy per current guidelines. This integrated clinical and laboratory investigation suggests that pathogen-specific factors, as shown in vitro and in a murine model, may influence the tempo of dissemination in human disease.